Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Ascendis Pharma A (ASND) over the last 7 years, with Q3 2025 value amounting to $400.2 million.

  • Ascendis Pharma A's Total Non-Current Liabilities rose 333.94% to $400.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $400.2 million, marking a year-over-year increase of 333.94%. This contributed to the annual value of $408.4 million for FY2024, which is 6167.9% up from last year.
  • Ascendis Pharma A's Total Non-Current Liabilities amounted to $400.2 million in Q3 2025, which was up 333.94% from $385.4 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Total Non-Current Liabilities peaked at $798.9 million during Q3 2023, and registered a low of $108.0 million during Q1 2021.
  • For the 5-year period, Ascendis Pharma A's Total Non-Current Liabilities averaged around $416.5 million, with its median value being $387.3 million (2024).
  • Per our database at Business Quant, Ascendis Pharma A's Total Non-Current Liabilities skyrocketed by 6173936.43% in 2021 and then tumbled by 6220.68% in 2023.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Total Non-Current Liabilities stood at $112.1 million in 2021, then skyrocketed by 496.4% to $668.4 million in 2022, then crashed by 62.21% to $252.6 million in 2023, then surged by 59.63% to $403.2 million in 2024, then decreased by 0.75% to $400.2 million in 2025.
  • Its last three reported values are $400.2 million in Q3 2025, $385.4 million for Q2 2025, and $384.7 million during Q1 2025.